PDGFRA Antibody for Soft Tissue Sarcoma.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 28187274.
- Also identified by DOI 10.1016/j.cell.2017.01.028.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Lartruvo (olaratumab) is a monoclonal antibody against the extracellular domain of PDGFRA. Olaratumab blocks ligand binding and thereby inhibits activation of PDGFRA kinase activity. Pre-clinically, this antibody inhibited PDGFRA-dependent tumor growth. In a randomized Phase II study, adding olaratumab to doxorubicin chemotherapy significantly improved overall survival, leading to FDA approval.
Medical subject headings
- Antibodies, Monoclonal
- Antineoplastic Agents
- Neoplasms